Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
IMVT
#1009
Immunovant, Inc. - Common Stock
41.1
9
USD
-0.06%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-6.00%
Monthly Change
+5.67%
6 month change
+50.49%
Year Change
+114.42%
Previous Close
43.8
2
Open
41.2
8
Low
41.0
9
High
41.4
8
Volume
1 501
Markets
US Stock Market
Healthcare
Biotechnology
IMVT
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
97.98 M
116.51 M
130.41 M
146.05 M
170.92 M
205.31 M
206.55 M
Valuation ratios
Enterprise value
1.17 B
148.13 M
1.65 B
3.98 B
2.21 B
4.2 B
8.2 B
Price to earnings ratio
—
-3.85
-9.07
-16.81
-6.26
-8.97
-15.51
Price to sales ratio
—
—
251.9
174.98
—
—
—
Price to cash flow ratio
—
5.7
10.14
20.38
6.89
-11.13
-19.58
Price to book ratio
—
1.29
5.27
7.07
3.66
5.31
2.61
Enterprise value to EBITDA ratio
-10.87
—
-7.82
-15.46
—
—
—
Profitability ratios
Return on assets %
-0.26
-0.3
-0.52
-0.39
-0.53
-0.53
-0.18
Return on equity %
-0.27
-0.33
-0.58
-0.42
-0.58
-0.59
-0.21
Return on invested capital %
-17.29 K
-14.49 K
-24.16 K
-54.49 K
-36.14 K
-25.26 K
-1 181.29
Gross margin %
100
—
100
100
—
—
—
Operating margin %
-38.24 K
—
-2 780.39
-1 033.19
—
—
—
EBITDA margin %
-38.22 K
—
-2 777.84
-1 032.27
—
—
—
Net margin %
-38.1 K
—
-2 783.85
-1 039.51
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
21.79
11.52
9.34
13.7
11.16
9.09
7.27
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0
—
0.02
0.05
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
-0.97
-1.53
-1.55
-2.48
-2.23
-2.23
EBIT per share
—
—
-1.71
-1.87
—
—
—
EBITDA per share
—
—
-1.71
-1.86
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
4.5
3.06
4.6
4.71
4.95
3.88
Net current asset value per share
—
4.68
3.29
4.82
5.06
5.2
4.14
Tangible book value per share
—
4.28
2.95
4.47
4.67
4.67
3.58
Working capital per share
—
4.27
2.93
4.47
4.61
4.63
3.57
Book value per share
—
4.28
2.95
4.47
4.67
4.67
3.58
News
Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress
Immunovant Stock: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy (IMVT)
Tracking Baker Brothers Portfolio: Q1 2026 Update
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential (NASDAQ:IMVT)
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy (NASDAQ:ROIV)
These Analysts Increase Their Forecasts On Immunovant After Q4 Results - Immunovant (NASDAQ:IMVT)
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data
These Two Biotech Stocks Rocketed — And One Just Broke Out
Amgen's Thyroid Eye Disease Data Rocks Rival Viridian, Makes It The Better Buy (AMGN)
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints